The patient starts with their arm straight, palm facing forwards and pushes the arm forwards and up against resistance
Administration : Ipamorelin is administered via injection, typically in a series of treatments spaced out over several weeks or months
What stood out: CagriSema achieved 23.0% weight loss at 84 weeks (efficacy estimand) Tirzepatide achieved 25.5% On the treatment-regimen estimand, weight loss was 20.2% vs 23.6% Primary endpoint not met: CagriSema did not demonstrate non-inferiority vs tirzepatide on weight loss at 84 weeks Why this matters This is a reminder that in obesity pharmacotherapy, very effective and best-in-class are not the same conversation
If you have suffered serious eye problems after using a GLP-1 drug, Schlesinger Law Offices may be able to help
The combination of all three (triple agonism) is the design hypothesis: act on appetite, insulin, and energy burn together, with the molecule tuned to be roughly nine times more active at the GIP receptor than the body's own GIP hormone, and somewhat less strongly active at the other two [2]
As for why GLP-1s might cause hair loss, the most likely explanation is the rapid or substantial weight loss that people can experience while on them, according to the authors
